ReviewFrontiers in immunology2021
Targeting the CD27-CD70 Pathway to Improve Outcomes in Both Checkpoint Immunotherapy and Allogeneic Hematopoietic Cell Transplantation.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Tracing cell communication programs across conditions at single cell resolution with CCC-RISE.bioRxiv : the preprint server for biology · 2026Article
- Potential CD27-CD70 interaction within adoptive T cells does not affect tumor antigen-specific T-cell immunotherapy.ImmunoHorizons · 2026Article
- Single-Cell RNA Sequencing Revealing Dysregulated Perturbations of Tregs in Psoriasis and Construction of a Treg-Related Diagnostic Model via a 101- Combination Machine Learning Computational FrameworkEndocrine, metabolic & immune disorders drug targets · 2026Article
- Intradermal immunization with Plasmodium berghei late-arresting genetically attenuated sporozoites induces PD-L1 expression on regulatory macrophages and dendritic cells.Scientific reports · 2025Article
- CD70 recruitment to the immunological synapse is dependent on CD20 in B cells.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Causal inference between immune cells and glioblastoma: a bidirectional Mendelian randomization study.Journal of Cancer · 2025Article
- A novel ubiquitin-related genes-based signature demonstrated values in prognostic prediction, immune landscape sculpture and therapeutic options in laryngeal cancer.Frontiers in pharmacology · 2025Article
- Tumor necrosis factor superfamily signaling: life and death in cancer.Cancer metastasis reviews · 2024Review
- CD27 signaling inhibits tumor growth and metastasis via CD8 + T cell-independent mechanisms in the B16-F10 melanoma model.Cancer immunology, immunotherapy : CII · 2024Article
- Predicting CD27 expression and clinical prognosis in serous ovarian cancer using CT-based radiomics.Journal of ovarian research · 2024Article
- Extracorporeal photopheresis as a promising strategy for the treatment of graft-versus-host disease after CAR T-cell therapy.Blood advances · 2024Article
- Review
- Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.Frontiers in immunology · 2024Review
- Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer.Journal for immunotherapy of cancer · 2023Article
- Comprehensive analysis of prognosis and immune function of CD70-CD27 signaling axis in pan-cancer.Functional & integrative genomics · 2023Article
- Phenotypic characterization of spatial immune infiltration niches in non-small cell lung cancer.Oncoimmunology · 2023Article
- Hub Genes in Non-Small Cell Lung Cancer Regulatory Networks.Biomolecules · 2022Article
- Constrast-enhanced computed tomography radiomics predicts CD27 expression and clinical prognosis in head and neck squamous cell carcinoma.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Immune checkpoint inhibitor therapies and allogeneic hematopoietic cell transplant (alloHCT) represent two distinct modalities that offer a chance for long-term cure in a diverse array of malignancies and have experienced many breakthroughs in recent years. Herein, we review the CD27-CD70 co-stimulatory pathway and its therapeutic potential in 1) combination with checkpoint inhibitor and other immune therapies and 2) its potential ability to serve as a novel approach in graft-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.